Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma

(2020) Cristina Kinahan et al.   Oncotarget

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

(2020) Flávia Alves Verza et al.   Cancers

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

(2020) Minjeong Yeon et al.   Frontiers in Cell and Developmental Biology

Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases

(2019) Barbara Frigerio et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*

(2019) Francine M. Foss et al.   LEUKEMIA & LYMPHOMA

Recent Advances in the Treatment of Peripheral T‐Cell Lymphoma

(2018) Kamel Laribi et al.   ONCOLOGIST

Histone Deacetylase Inhibitors as Anticancer Drugs

(2017) Tomas Eckschlager et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Methotrexate and Pralatrexate

(2015) Gary S. Wood et al.   DERMATOLOGIC CLINICS

Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine or Cytarabine Treatment

(2014) Godefridus J. Peters et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma

(2013) Ana A Tula-Sanchez et al.   CANCER BIOLOGY & THERAPY

Pralatrexate Pharmacology and Clinical Development

(2013) E. Marchi et al.   CLINICAL CANCER RESEARCH

Pralatrexate: evaluation of clinical efficacy and toxicity in T-cell lymphoma

(2013) Alexei Shimanovsky et al.   EXPERT OPINION ON PHARMACOTHERAPY

The role of epigenetics in malignant pleural mesothelioma

(2013) Fabian Vandermeers et al.   LUNG CANCER

Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo

(2013) Wenwen Chien et al.   MOLECULAR CARCINOGENESIS

Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer

(2012) Dmitriy I Dovzhanskiy et al.   BMC CANCER

Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance

(2012) Nitzan Gonen et al.   DRUG RESISTANCE UPDATES

Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer

(2011) Leonie H.A.M. de Wilt et al.   BIOCHEMICAL PHARMACOLOGY

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells

(2010) I.V. Bijnsdorp et al.   BIOCHEMICAL PHARMACOLOGY

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity

(2010) M Serova et al.   BRITISH JOURNAL OF CANCER

Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies

(2010) E. Marchi et al.   CLINICAL CANCER RESEARCH

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

(2010) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways

(2009) Jung Jin Hwang et al.   ANTI-CANCER DRUGS

Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients

(2009) Joost W. Van Der Heijden et al.   ARTHRITIS AND RHEUMATISM

Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues

(2009) Rongbao Zhao et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

A novel loss-of-function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function

(2008) I. Lasry et al.   BLOOD

Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo

(2008) Robert Mauritz et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation

(2008) Ilan Ifergan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Proton-Coupled Folate Transporter: Impact on Pemetrexed Transport and on Antifolates Activities Compared with the Reduced Folate Carrier

(2008) R. Zhao et al.   MOLECULAR PHARMACOLOGY